Published in Hum Mol Genet on November 01, 1999
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr (2006) 2.97
The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol (2005) 2.39
Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis (2004) 1.86
Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet (2007) 1.76
Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis (2007) 1.39
Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J (2005) 1.24
Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. Biochem J (2001) 1.15
The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol (2013) 1.09
Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis (2011) 1.03
Expression systems and species used for transgenic animal bioreactors. Biomed Res Int (2013) 0.85
Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. J Inherit Metab Dis (2010) 0.82
Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis (2016) 0.82
Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease. Gene Ther (2010) 0.81
Enzyme replacement and beyond. J Inherit Metab Dis (2001) 0.80
Could protein tertiary structure influence mammary transgene expression more than tissue specific codon usage? Transgenic Res (2010) 0.78
Expression of Active Fluorophore Proteins in the Milk of Transgenic Pigs Bypassing the Secretory Pathway. Sci Rep (2016) 0.75
A review of treatment of Pompe disease in infants. Biologics (2007) 0.75
Monitoring of Venus transgenic cell migration during pregnancy in non-transgenic rabbits. Transgenic Res (2016) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Major transcript of the frameshifted coxII gene from trypanosome mitochondria contains four nucleotides that are not encoded in the DNA. Cell (1986) 5.49
Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J Cell Biol (1994) 3.65
Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell (1997) 3.17
Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol (1988) 2.63
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex. EMBO J (1988) 2.44
Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci U S A (1982) 2.39
Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature (1993) 2.36
Mammalian Golgi-associated Bicaudal-D2 functions in the dynein-dynactin pathway by interacting with these complexes. EMBO J (2001) 2.34
Lysophosphatidic acid, but not phosphatidic acid, is a potent Ca2(+)-mobilizing stimulus for fibroblasts. Evidence for an extracellular site of action. J Biol Chem (1990) 2.31
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain (2005) 2.25
The POU factor Oct-6 and Schwann cell differentiation. Science (1996) 2.17
Identification of a putative membrane receptor for the bioactive phospholipid, lysophosphatidic acid. EMBO J (1992) 1.97
Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet (2000) 1.84
Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet (1995) 1.81
Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ (1993) 1.80
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet (1999) 1.76
Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p21ras pathway. J Biol Chem (1994) 1.72
Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord (2010) 1.62
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology (2007) 1.61
Introduction of a viral thymidine kinase gene and the human beta-globin gene into developmentally multipotential mouse teratocarcinoma cells. Proc Natl Acad Sci U S A (1980) 1.58
A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy. Mol Cell (1998) 1.52
Gi-mediated activation of the p21ras-mitogen-activated protein kinase pathway by alpha 2-adrenergic receptors expressed in fibroblasts. J Biol Chem (1993) 1.48
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest (1987) 1.45
Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II. J Biol Chem (1985) 1.43
cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J Biol Chem (1994) 1.38
Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology (2004) 1.37
Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology (2005) 1.35
Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods (1993) 1.33
The biologically active phospholipid, lysophosphatidic acid, induces phosphatidylcholine breakdown in fibroblasts via activation of phospholipase D. Comparison with the response to endothelin. Biochem J (1992) 1.33
Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem (1993) 1.32
Tay-Sachs and Sandhoff's disease: intergenic complementation after somatic cell hybridization. Exp Cell Res (1974) 1.32
TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum Mol Genet (2001) 1.31
Lysophosphatidic acid: a bioactive phospholipid with growth factor-like properties. Rev Physiol Biochem Pharmacol (1992) 1.27
Characterization of the human lysosomal alpha-glucosidase gene. Biochem J (1990) 1.26
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis (2001) 1.25
Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J (1990) 1.24
Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet (1983) 1.22
Determination of Gaucher's disease phenotypes with monoclonal antibody. Clin Chim Acta (1983) 1.22
Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet (1978) 1.20
An Arabidopsis gene encoding a chloroplast-targeted beta-amylase. Plant J (1999) 1.20
Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem (1993) 1.18
Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun (1994) 1.17
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord (2008) 1.15
Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem (1991) 1.15
Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet (1998) 1.14
The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet (1994) 1.14
Biosynthesis and intracellular transport of alpha-glucosidase and cathepsin D in normal and mutant human fibroblasts. Eur J Biochem (1985) 1.13
Genetic heterogeneity in GM1-gangliosidosis. Nature (1975) 1.11
Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol (1994) 1.09
Glycogenosis type II (acid maltase deficiency). Muscle Nerve Suppl (1995) 1.09
Monoclonal antibodies against human beta-glucocerebrosidase. Eur J Biochem (1983) 1.08
Metabolic conversion of the biologically active phospholipid, lysophosphatidic acid, in fibroblasts. Biochim Biophys Acta (1992) 1.08
Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm Park Dis Dement Sect (1993) 1.05
Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites. Biochem J (1993) 1.05
Isolation and characterization of a precursor form of lysosomal alpha-glucosidase from human urine. Eur J Biochem (1984) 1.05
Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype. J Med Genet (1996) 1.01
A distal Schwann cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral nerve development and regeneration. EMBO J (2000) 1.01
Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J Biol Chem (2000) 1.00
Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase. Eur J Biochem (1995) 0.99
GM1-gangliosidosis. Defective recognition site on beta-galactosidase precursor. J Biol Chem (1986) 0.99
Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest (1991) 0.99
Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J Exp Med (1994) 0.99
Individual and interindividual differences in binocular retinal rivalry in man. Psychophysiology (1966) 0.98
Comparison of sequence and function of the Oct-6 genes in zebrafish, chicken and mouse. Mech Dev (1998) 0.97
Soluble human interleukin-6 receptor. Expression in insect cells, purification and characterization. Eur J Biochem (1995) 0.96
Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet (1998) 0.96
Branching and differentiation defects in pulmonary epithelium with elevated Gata6 expression. Mech Dev (2001) 0.96
Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells. J Neurol (1988) 0.96
Involvement of the Arg179 in the active site of human IL-6. Eur J Biochem (1993) 0.96
Cotransfer of syntenic human genes into mouse cells using isolated metaphase chromosomes or cellular DNA. Hum Genet (1985) 0.96
The subcellular localization of soluble and membrane-bound lysosomal enzymes in I-cell fibroblasts: a comparative immunocytochemical study. Eur J Cell Biol (1985) 0.95
Asymptomatic and late-onset ornithine transcarbamylase (OTC) deficiency in males of a five-generation family, caused by an A208T mutation. Clin Genet (1996) 0.95
Glycogenosis type II: protein and DNA analysis in five South African families from various ethnic origins. Am J Hum Genet (1989) 0.94
Enhanced proteolytic degradation of normal beta-galactosidase in the lysosomal storage disease with combined beta-galactosidase and neuraminidase deficiency. Biochim Biophys Acta (1982) 0.93
Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord (2007) 0.93
Ganglioside storage, hexosaminidase lability, and urinary oligosaccharides in adult Sandhoff's disease. Neurology (1987) 0.92
A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology (1999) 0.92